keyword
MENU ▼
Read by QxMD icon Read
search

Drug pricing

keyword
https://www.readbyqxmd.com/read/29789291/is-ontario-adding-drug-prices-to-emrs
#1
Wendy Glauser
No abstract text is available yet for this article.
May 22, 2018: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://www.readbyqxmd.com/read/29788203/do-cost-containment-policies-save-money-and-influence-physicians-prescribing-behavior-lessons-from-south-korea-s-drug-policy-for-diabetes-medication
#2
Shin-On Kang, Seung Ju Kim, Sohee Park, Sung-In Jang, Eun-Cheol Park
Objective: We evaluate the effects of drug price reduction policy on pharmaceutical expenditure and prescription patterns in diabetes medication. Design: An interrupted time series study design using generalized estimating equations. Setting: This study used National Health Insurance claim data from 2010 to 2013. Participants: A total of 68 127 diabetes patients and 12 465 hospitals. Intervention(s): The drug price reduction policy...
May 17, 2018: International Journal for Quality in Health Care
https://www.readbyqxmd.com/read/29779693/a-new-strategy-to-reduce-us-drug-prices
#3
Talha Khan Burki
No abstract text is available yet for this article.
May 17, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29778265/a-guide-to-the-economics-of-hepatitis-c-virus-cure-in-2017
#4
REVIEW
Benjamin P Linas, Shayla Nolen
This commentary reviews the core principals of cost-effectiveness and applies them to the rapidly evolving context of hepatitis C virus treatment in the United States. The article provides a foundation of evidence that hepatitis C virus treatment provides good economic value, even though it is expensive, and even when treating people who inject drugs who are at high risk for hepatitis C virus reinfection. The price of medications has decreased, but the high price continues to limit access to care. This wedge between cost effectiveness and affordability stands front and center as one of the leading obstacles to elimination...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29777433/are-pcsk9-inhibitors-cost-effective
#5
Max J Korman, Kjetil Retterstøl, Ivar Sønbø Kristiansen, Torbjørn Wisløff
The objective of this study was to review available health economic evaluations of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. These drugs reduce low-density lipid cholesterol levels and cardiovascular risk, but their cost effectiveness has been questioned. We searched Medline and Embase for economic evaluations in any language at any time. Studies were included if they analysed any PCSK9 inhibitor compared with either statin alone or in combination with ezetimibe or any other therapy considered standard prior to the introduction of PCSK9 inhibitors...
May 18, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29775778/the-genus-cordyceps-an-extensive-review-of-its-traditional-uses-phytochemistry-and-pharmacology
#6
REVIEW
Opeyemi Joshua Olatunji, Jian Tang, Adesola Tola, Florence Auberon, Omolara Oluwaniyi, Zhen Ouyang
The genus Cordyceps has about 750 identified species which are distributed in many regions of the World, but mainly found in South Asia, Europe and North America. The species of the genus are highly priced and are widely used as food and medicine for the treatment of various ailments. This present review compiles literature information on the ethno-medicinal, phytochemistry and pharmacological properties of species in the genus Cordyceps. In addition, the review also suggest recommendations for the future researches...
May 15, 2018: Fitoterapia
https://www.readbyqxmd.com/read/29772018/the-cost-effectiveness-of-bevacizumab-ranibizumab-and-aflibercept-for-the-treatment-of-age-related-macular-degeneration-a-cost-effectiveness-analysis-from-a-societal-perspective
#7
Freekje van Asten, Charlotte T J Michels, Carel B Hoyng, Gert Jan van der Wilt, B Jeroen Klevering, Maroeska M Rovers, Janneke P C Grutters
BACKGROUND: The discussion on the use of bevacizumab is still ongoing and often doctors are deterred from using bevacizumab due to legal or political issues. Bevacizumab is an effective, safe and inexpensive treatment option for neovascular age-related macular degeneration (AMD), albeit unregistered for the disease. Therefore, in some countries ophthalmologists use the equally effective but expensive drugs ranibizumab and aflibercept. We describe the economic consequences of this dilemma surrounding AMD treatment from a societal perspective...
2018: PloS One
https://www.readbyqxmd.com/read/29770440/approaches-to-increase-mechanistic-understanding-and-aid-in-the-selection-of-precipitation-inhibitors-for-supersaturating-formulations-a-pearrl-review
#8
REVIEW
Daniel J Price, Felix Ditzinger, Niklas J Koehl, Sandra Jankovic, Georgia Tsakiridou, Anita Nair, René Holm, Martin Kuentz, Jennifer B Dressman, Christoph Saal
OBJECTIVES: Supersaturating formulations hold great promise for delivery of poorly soluble active pharmaceutical ingredients (APIs). To profit from supersaturating formulations, precipitation is hindered with precipitation inhibitors (PIs), maintaining drug concentrations for as long as possible. This review provides a brief overview of supersaturation and precipitation, focusing on precipitation inhibition. Trial-and-error PI selection will be examined alongside established PI screening techniques...
May 16, 2018: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/29769386/global-acceptance-of-biosimilars-importance-of-regulatory-consistency-education-and-trust
#9
REVIEW
Eduardo Cazap, Ira Jacobs, Ali McBride, Robert Popovian, Karol Sikora
Globally, biosimilars are expected to have a key role in improving patient access to biological therapies and addressing concerns regarding the escalating cost of health care. Indeed, in Europe, increased use of biologics and reduced drug prices have been observed after the introduction of biosimilars. Recently, several monoclonal antibody biosimilars of anticancer therapies have been approved, and numerous others are in various stages of clinical development. Biosimilars are authorized via a regulatory pathway separate from that used for generic drugs; they are also regulated separately from novel biologics...
May 16, 2018: Oncologist
https://www.readbyqxmd.com/read/29767322/management-of-cardiogenic-shock-complicating-myocardial-infarction
#10
REVIEW
Alexandre Mebazaa, Alain Combes, Sean van Diepen, Alexa Hollinger, Jaon N Katz, Giovanni Landoni, Ludhmila Abrahao Hajjar, Johan Lassus, Guillaume Lebreton, Gilles Montalescot, Jin Joo Park, Susanna Price, Alessandro Sionis, Demetris Yannopolos, Veli-Pekka Harjola, Bruno Levy, Holger Thiele
Up to 10% of acute coronary syndromes are complicated by cardiogenic shock (CS) with contemporary mortality rates of 40-50%. The extent of ischemic myocardium has a profound impact on the initial, in-hospital, and post-discharge management and prognosis in this patient population. Individualized patient risk assessment plays an important role in determining appropriate revascularization, drug treatment with inotropes and vasopressors, mechanical circulatory support, intensive care support of other organ systems, hospital level of care triage, and allocation of clinical resources...
May 16, 2018: Intensive Care Medicine
https://www.readbyqxmd.com/read/29766592/scoring-the-best-deal-quantity-discounts-and-street-price-variation-of-diverted-oxycodone-and-oxymorphone
#11
Jacob A Lebin, David L Murphy, Stevan Geoffrey Severtson, Gabrielle E Bau, Nabarun Dasgupta, Richard C Dart
BACKGROUND: Diverted prescription opioids are significant contributors to drug overdose mortality. Street price has been suggested as an economic metric of the diverted prescription opioid black market. This study examined variables that may influence the street price of diverted oxycodone and oxymorphone. METHODS: A cross-sectional study was conducted utilizing data from the previously validated, crowdsourcing website StreetRx. Street price reports of selected oxycodone and oxymorphone products, between August 22, 2014 and June 30, 2016, were considered for analysis...
May 15, 2018: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29764677/a-novel-in-house-mixed-mode-solid-phase-extraction-of-urine-for-the-determination-of-16-basic-drugs-by-hplc-ion-trap-ms
#12
Giacomo Musile, Lucia Cenci, Elena Piletska, Rossella Gottardo, Alessandra M Bossi, Federica Bortolotti
The aim of the present work was to develop a novel in-house mixed-mode SPE sorbent to be used for the HPLC-Ion TrapMS determination of 16 basic drugs in urine. By using a computational modelling, a virtual monomer library was screened identifying three suitable functional monomers, methacrylic acid (MAA), itaconic acid (IA) and 2-acrylamide-2-methylpropane sulfonic acid (AMPSA), respectively. Three different sorbents were then synthetized based on these monomers, and using as cross-linker trimethylolpropane trimethacrylate (TMPTMA)...
May 9, 2018: Journal of Chromatography. A
https://www.readbyqxmd.com/read/29763404/indication-specific-drug-pricing-simple-in-theory-complex-in-reality
#13
Sarah Kwon
Although outcome-based pricing has proven to be more popular, experts and industry insiders say indication-specific pricing should be getting more attention, especially in oncology. But will administrative costs offset any benefit? And legal and regulatory obstacles could get in the way.
May 2018: Managed Care
https://www.readbyqxmd.com/read/29763403/cost-of-cancer-drugs-something-has-to-give
#14
Eric Bender
The drugs often are more effective and have fewer side effects. The science-often just amazing. Medically, cancer treatment has never been in a better place. But are high prices making it unaffordable? Payers, providers, policymakers, and drugmakers themselves are wrestling with the issue. Meanwhile, many patients are being priced out of treatments that could save their lives.
May 2018: Managed Care
https://www.readbyqxmd.com/read/29761351/economic-evaluation-of-stiripentol-for-dravet-syndrome-a-cost-utility-analysis
#15
Jesse Elliott, Bláthnaid McCoy, Tammy Clifford, George A Wells, Doug Coyle
BACKGROUND: Dravet syndrome is a catastrophic form of pediatric treatment-resistant epilepsy with few effective treatment options. Stiripentol is approved for use in Canada for treatment of Dravet syndrome, but the associated long-term costs and benefits have not been well-studied and its cost effectiveness is unclear. OBJECTIVE: The aim of this study was to evaluate the cost effectiveness of stiripentol as an adjunctive treatment to clobazam and valproate for treatment of Dravet syndrome from the perspective of the Canadian public healthcare payer...
May 15, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29760505/low-value-approvals-and-high-prices-might-incentivize-ineffective-drug-development
#16
Vinay Prasad, Christopher McCabe, Sham Mailankody
No abstract text is available yet for this article.
May 14, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29760170/trump-promises-to-reduce-drug-prices-but-drops-campaign-promises
#17
Janice Hopkins Tanne
No abstract text is available yet for this article.
May 14, 2018: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/29759512/drug-eluting-stents-versus-bare-metal-stents-in-saphenous-vein-grafts-a-double-blind-randomised-trial
#18
Emmanouil S Brilakis, Robert Edson, Deepak L Bhatt, Steven Goldman, David R Holmes, Sunil V Rao, Kendrick Shunk, Bavana V Rangan, Kreton Mavromatis, Kodangudi Ramanathan, Anthony A Bavry, Santiago Garcia, Faisal Latif, Ehrin Armstrong, Hani Jneid, Todd A Conner, Todd Wagner, Judit Karacsonyi, Lauren Uyeda, Beverly Ventura, Aaron Alsleben, Ying Lu, Mei-Chiung Shih, Subhash Banerjee
BACKGROUND: Few studies have examined the efficacy of drug-eluting stents (DES) for reducing aortocoronary saphenous vein bypass graft (SVG) failure compared with bare-metal stents (BMS) in patients undergoing stenting of de-novo SVG lesions. We assessed the risks and benefits of the use of DES versus BMS in de-novo SVG lesions. METHODS: Patients were recruited to our double-blind, randomised controlled trial from 25 US Department of Veterans Affairs centres. Eligible participants were aged at least 18 years and had at least one significant de-novo SVG lesion (50-99% stenosis of a 2·25-4·5 mm diameter SVG) requiring percutaneous coronary intervention with intent to use embolic protection devices...
May 11, 2018: Lancet
https://www.readbyqxmd.com/read/29757315/a-multi-center-prospective-cohort-study-to-evaluate-the-effect-of-differential-pricing-and-health-systems-strengthening-on-access-to-medicines-and-management-of-hypertension-and-diabetes-in-ghana-a-study-protocol
#19
Linda Meta Mobula, Stephen Sarfo, Lynda Arthur, Gilbert Burnham, Jacob Plange-Rhule, Daniel Ansong, Edith Gavor, David Ofori-Adjei
Background: There is evidence to suggest that the prevalence of non-communicable diseases (NCDs), in particular cardiovascular diseases and diabetes, are being recognized as forming a substantial proportion of the burden of disease among populations in Low- and Middle-Income Countries (LMICs).  Access to treatment is likely a key barrier to the control and prevention of NCD outcomes.  Differential pricing, an approach used to price drugs based on the purchasing power of patients in different socioeconomic segments, has been shown to be beneficial and leads to improved access and affordability...
February 7, 2018: Gates open research
https://www.readbyqxmd.com/read/29757040/cost-savings-for-biosimilars-in-the-united-states-a-theoretical-framework-and-budget-impact-case-study-application-using-filgrastim
#20
Simrun Grewal, Scott Ramsey, Sanjeev Balu, Josh J Carlson
OBJECTIVE: Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U.S. METHODS: We developed a framework to illustrate how key factors including regulatory policies, provider and patient perception, pricing, and payer policies impact biosimilar cost-savings...
May 14, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
keyword
keyword
109177
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"